ObjectivesOur objective was to identify surgical–pathologic factors affecting prognosis in stage IB non–small cell lung cancers.MethodsBetween 1997 and 2006, a cohort of 272 cases of pT2 N0 M0 stage lung cancer were retrospectively analyzed. The patients included 70 women and 202 men with a mean age of 67.0 years. The surgical resections included pneumonectomy in 4, bilobectomy or lobectomy in 217, and limited resections in another 51. The impact of surgical–pathologic characteristics on survival, including cell type, tumor differentiation, tumor size, depth of visceral pleural invasion, type of surgical resection, and extent of lymphadenectomy on patient survival, was compared accordingly.ResultsTumor types included adenocarcinoma/bronchio...
Background:During the period that randomized clinical trials were establishing the role of adjuvant ...
Introduction:The appropriate therapeutic strategy and postoperative management for patients with sta...
Patients with stage IIIA-ipsilateral mediastinal lymph node involvement (N2) non–small cell lung can...
ObjectivesOur objective was to identify surgical–pathologic factors affecting prognosis in stage IB ...
ABSTRACT: Significant heterogenity of stage IB (sixth edition of the TNM staging system) nonsmall ce...
AbstractObjective: Prognostic relevance of the current TNM stage grouping for lung cancer is still a...
AbstractObjective: The TNM staging system of lung cancer is widely used as a guide for estimating pr...
AbstractObjectivesNon–small cell lung cancer with mediastinal lymph node involvement is a heterogene...
IntroductionPatients with stage II non-small cell lung carcinoma (NSCLC) represent a heterogeneous s...
AbstractBackground: Clinical trials dealing with multimodal strategy for N2 non–small cell lung canc...
Introduction:Therapeutic strategies remain controversial for the completely resected stage I non-sma...
ObjectiveResection is the treatment of choice for patients with stage I non–small cell lung cancer. ...
ObjectiveUsing a national cancer registry, we determined the postoperative survival of patients with...
AbstractWe attempted to clarify what factors predominantly influence the survival of patients with n...
AbstractObjective: Many reports have raised certain problems concerning the current TNM classificati...
Background:During the period that randomized clinical trials were establishing the role of adjuvant ...
Introduction:The appropriate therapeutic strategy and postoperative management for patients with sta...
Patients with stage IIIA-ipsilateral mediastinal lymph node involvement (N2) non–small cell lung can...
ObjectivesOur objective was to identify surgical–pathologic factors affecting prognosis in stage IB ...
ABSTRACT: Significant heterogenity of stage IB (sixth edition of the TNM staging system) nonsmall ce...
AbstractObjective: Prognostic relevance of the current TNM stage grouping for lung cancer is still a...
AbstractObjective: The TNM staging system of lung cancer is widely used as a guide for estimating pr...
AbstractObjectivesNon–small cell lung cancer with mediastinal lymph node involvement is a heterogene...
IntroductionPatients with stage II non-small cell lung carcinoma (NSCLC) represent a heterogeneous s...
AbstractBackground: Clinical trials dealing with multimodal strategy for N2 non–small cell lung canc...
Introduction:Therapeutic strategies remain controversial for the completely resected stage I non-sma...
ObjectiveResection is the treatment of choice for patients with stage I non–small cell lung cancer. ...
ObjectiveUsing a national cancer registry, we determined the postoperative survival of patients with...
AbstractWe attempted to clarify what factors predominantly influence the survival of patients with n...
AbstractObjective: Many reports have raised certain problems concerning the current TNM classificati...
Background:During the period that randomized clinical trials were establishing the role of adjuvant ...
Introduction:The appropriate therapeutic strategy and postoperative management for patients with sta...
Patients with stage IIIA-ipsilateral mediastinal lymph node involvement (N2) non–small cell lung can...